In addition, fludarabine and cyclophosphamide, which were routinely used before CAR-T therapy, down-regulated IDO expression in lymphoma cells and improved the anti-tumor activity of CD19-CAR-T in vivo [66]. The gene discussed is IDO1; the disease is neoplasm.